“As scale and member balances increase, we see little justification for schemes to charge both a fixed membership fee and a base management fee, which is typically percentage-based.” At the end of December, KiwiSaver schemes held investments worth more than $76 billion for their members, figures from fund research company Morningstar showed. KiwiSaver membership fees vary between provider, but the last FMA KiwiSaver annual report showed KiwiSavers paid just under $85 million in membership fees in the 12 months to the end of March 2020. “We expect to see KiwiSaver schemes move towards eliminating membership fees from their fee structures,” the FMA said.
Tips from the Commission for Financial Capability can help people in the 45 and under, 46-65, and 65-plus age groups get the most out of KiwiSaver. (First published May 2018.)
All eyes on Contact, Meridian as S&P index rebalancing looms
8 Apr, 2021 05:30 AM
4 minutes to read
Contact Energy s Clyde Dam. Photo / Grant Bradley, NZ Herald
Shares in Contact and Meridian look likely to remain on a rocky road until key index changes take effect on April 16. Trade in both stocks has been extremely volatile as clean, green power generators have became flavour of the month for exchange traded funds (ETFs).
BlackRock - the world s biggest asset manager - has two iShares clean energy exchange traded funds (ETFs) which have amassed big stakes in Meridian Contact.
Both funds track the S&P Dow Jones Global Clean Index.
Cannabis company Medical Kiwi declined NZX listing
9 Apr, 2021 01:00 AM
6 minutes to read
Medical Kiwi has been denied a listing on the NZX. Photo / 123RF
Cannabis company Medical Kiwi - the subject of ongoing inquiries by the financial markets regulator - has been denied a listing on the NZX. NZ RegCo chief executive, Joost van Amelsfort, responsible for NZX regulation, confirmed the stock exchange has declined Medical Kiwi s application and determined the company is not suitable for a direct listing at this time.
A Financial Markets Authority (FMA) spokesman said its investigations into the company are ongoing.
Medical Kiwi s chairman and executive director, Aldo Miccio, rejected the characterisation that his firm s application has been declined.